Crelux has developed a bi-turbo vector system which allows to express target proteins in parallel in E.coli and insect cells from the same plasmid construct. This procedure helps to produce pure proteins for x-ray structure analysis and for drug discovery purposes. The acquisition is in line with the rapid development of WuXi European operations.
China Bio news release, April 20, 2016
China’s WuXi Pharma Tech acquires Munich-based Crelux, a protein company